Celladon Corporation is a biotechnology company focused on developing cutting edge treatments for cardiovascular diseases. Celladon’s lead development program is designed to treat congestive heart failure by using a recombinant adeno-associated viral (AAV) vector to restore production of an enzyme that regulates calcium cycling and contractility in heart muscle cells. Celladon's first generation product, MYDICAR®, replaces the gene for the SERCA2a enzyme, which is known to be depleted in severe heart failure. One year data from the Phase 2 CUPID clinical trial demonstrate that restoring SERCA2a enzyme production provides sustained improvements in ventricular function and multiple cardiac parameters in patients with advanced heart failure.

 The following materials are available for your use in PDF format:

1) Product Development Backgrounder

2) MYDICAR® Fact Sheet